Radiation & Nausea Focus Target opportunities in partnerships or licensing for pain products addressing opioid induced nausea and vomiting (OINV), postoperative nausea and vomiting (PONV), chemotherapy induced nausea and vomiting (CINV), and radiation induced nausea and vomiting (RINV), appealing to hospitals, surgical centers, and oncology clinics seeking safer multi-modal pain management.

Opioid Adjunct Demand Position Charleston Laboratories as a source for non acetaminophen formulations with reduced liver injury risk and potential abuse deterrence technologies, aligning with pain management programs and pharmaceutical companies looking to expand non-opioid or adjunct therapies.

Strategic Alliances Leverage their interest in discovery and commercialization alliances to pursue co-development or co-marketing deals with mid-market pharma, contract research organizations, or academic partnerships to accelerate pipeline advancement and market entry.

Clinical Milestones Capitalize on past Phase 3 CL-108 communications and leadership hires in regulatory affairs and medical oversight to target investors and partners who value established regulatory expertise and clear clinical progression for faster approvals and market access.

Sustainability & Safety Narrative Promote the safety profile and nausea mitigation focus to win supply chain and payer engagement, stressing reduced adverse events and potential cost savings for hospitals and insurers, enhancing value proposition for formulary discussions.